Combined with the significantly better outcomes in SMZL patients with activated Notch2 alleles [65], one has to wonder about the role of the immune environment in onset and progression of human SMZL patients with Notch2 mutations. This evidence concerns the gene NOTCH2 and splenic marginal zone lymphoma.